Two female patients developed a severe, painful proximal myopathy after taking 18-30 g of epsilonaminocaproic acid daily for 5 weeks. Marked elevations of serum aminotransferases, creatine kinase and aldolase levels were found and the first patient had electromyographic and muscle biopsy changes of an acute monophasic, necrotizing myopathy at the height of the illness. Resolution occurred in both cases on stopping the drug and the second patient had no electromyographic or muscle biopsy abnormalities 3 weeks later. Only 2 recognized cases of the condition have been reported previously but a review of the literature revealed several other possible examples.
Introduction
Epsilon aminocaproic acid (EACA) is an antifibrinolytic agent used in the management of certain haemorrhagic disorders (Martindale, 1977) and in the treatment of hereditary angioneurotic oedema (HAO) since it inhibits the C'1 component of complement (Korsan-Bengsten et al., 1969) . Mild side effects, such as diarrhoea, postural hypotension, dizziness, allergic reactions and dyspepsia are common. Less frequently, microthrombosis, venous thrombosis and pulmonary embolism can occur (Martindale, 1977) . Myopathy has only rarely been described as a side effect of EACA therapy (KorsanBengsten et al., 1969; Bennett, 1972) (180 i.u./l) (Fig. 1) 
Discussion
Only 2 reports of EACA myopathy have appeared previously (Korsan-Bengsten et al., 1969; Bennett, 1972) but cases of painful proximal myopathy attributable to the drug have been mentioned by several other authors (Frank et al., 1972; Erill, Cabezas and Ausina, 1974; Shaw and Miller, 1974) . Table 1 illustrates the daily doses of drug administered and the length of time for which the drug was taken before symptoms developed in each case. The 2 cases described here illustrate the typical syndrome. Muscle pain and tenderness are usually the earliest symptoms, rapidly followed by weakness with widespread involvement of proximal and axial muscles, the neck muscles being unaffected. Myoglobinuria may occur, together with marked elevation of serum enzyme levels reflecting the severity of the myopathy. The present cases also illustrate the reversibility of the myopathy on withdrawing the drug.
The fact that symptoms only appear after 4-6 weeks of treatment with daily doses of 18-30 g suggests a cumulative dose-related effect. However, many patients have taken up to 32 g daily for long periods without developing a myopathy (Korsan- Bengsten et al., 1969) , raising the possibility of an idiosyncratic reaction. The relevance of hypokalaemia in the development of the myopathy in Case 1 is conjectural. Hypokalaemia itself can cause muscle weakness and might therefore be a precipitatory factor but changes in K+ level were not noted in any other case.
